Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease
(2015) In BMC Neurology 15.- Abstract
- Background: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia. Methods: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias. Results: We observed similar plasma anti-PC levels in controls, patients with... (More)
- Background: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia. Methods: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias. Results: We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias. Conclusions: Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5186101
- author
- Silajdzic, Edina LU ; Björkqvist, Maria LU and Hansson, Oskar LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Anti-phosphorylcholine, Alzheimer's disease, Dementia, Biomarker
- in
- BMC Neurology
- volume
- 15
- article number
- 8
- publisher
- BioMed Central (BMC)
- external identifiers
-
- wos:000349352800001
- scopus:84924086826
- pmid:25651913
- ISSN
- 1471-2377
- DOI
- 10.1186/s12883-015-0260-1
- language
- English
- LU publication?
- yes
- id
- f62a3127-e2b5-4205-85ee-bb5c61df8f21 (old id 5186101)
- date added to LUP
- 2016-04-01 14:01:58
- date last changed
- 2023-09-03 08:43:15
@article{f62a3127-e2b5-4205-85ee-bb5c61df8f21, abstract = {{Background: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia. Methods: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias. Results: We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias. Conclusions: Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease.}}, author = {{Silajdzic, Edina and Björkqvist, Maria and Hansson, Oskar}}, issn = {{1471-2377}}, keywords = {{Anti-phosphorylcholine; Alzheimer's disease; Dementia; Biomarker}}, language = {{eng}}, publisher = {{BioMed Central (BMC)}}, series = {{BMC Neurology}}, title = {{Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease}}, url = {{https://lup.lub.lu.se/search/files/3732898/7889919}}, doi = {{10.1186/s12883-015-0260-1}}, volume = {{15}}, year = {{2015}}, }